Vijaya Diagnostic Centre Limited has informed the Exchange about change in Management
VIJAYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vijaya Diagnostic Centre's board, meeting on February 13, 2026, approved Q3 FY26 results and announced major management changes. CFO Mr. S. Ramachandra Reddy stepped down due to organizational restructuring but will continue as General Manager – Finance & Accounts. Mr. Ankit Shah (ex-Group CFO of Incor Hospitals/OMNI Hospitals) was named new CFO, Mr. Sai Siva Prasad (ex-UnitedHealth/Optum) as CTO, and Mr. Venkata Siva Rama Raju Vegesna (ex-KIMS Hospitals) as COO. The board also appointed two new Independent Directors — Mr. Ravi Shankararamiah (Senior Advocate) and Dr. Sasikala Paruchuri Kola (Consultant Gynaecologist) — each for 5-year terms. Additionally, 1,15,000 ESOPs were granted at ₹809 per option under the VDCL ESOP Plan 2018, and the Related Party Transaction policy was revised per updated SEBI norms.
The reshuffle brings in senior external leadership across finance, technology, and operations, which is generally a positive governance signal, though it comes with a simultaneous CFO exit. The stock may react to the mix of fresh expertise and continuity (outgoing CFO stays in finance team). No material financial numbers beyond the ESOP grant price (₹809) were disclosed in this filing — Q3 results would be in a separate disclosure.